The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Forecasted Rise In Market Size Of The Buminate Market During The Forecast Period?
The historical growth can be ascribed to the well-established clinical application of albumin, an increase in surgical procedures, the expansion of critical care units, its demonstrated safety profile, and a rising dependence on plasma-derived therapies.
The anticipated growth during the forecast period is primarily driven by an escalation in trauma incidents, an increase in surgical procedures, the expansion of intensive care unit infrastructure, the growing need for rapid volume restoration, and enhanced capabilities in plasma fractionation.
Significant trends expected within the forecast period include the ongoing application of albumin in critical care settings, a surging demand in the management of trauma and burns, the broadening of surgical volume support therapies, a notable preference for plasma-derived proteins, and an overall rise in intensive care admissions.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20008&type=smp
Which Significant Factors Are Encouraging Growth In The Buminate Market?
The growth of the Buminate market is anticipated to be fueled by the escalating occurrence of liver diseases. These conditions encompass various ailments that impair liver function, such as cirrhosis, hepatitis, fatty liver disease, and liver cancer, frequently stemming from infections, toxins, genetic factors, or chronic alcohol consumption. The rise in liver disease prevalence is largely attributed to poor lifestyle and dietary choices, where excessive alcohol intake, an unhealthy diet, and obesity contribute to liver damage and the accumulation of fat. Buminate, a human albumin solution, assists in managing liver diseases by re-establishing and sustaining blood volume and osmotic pressure in patients suffering from conditions like cirrhosis or liver failure. This action enhances circulation, supports appropriate fluid balance, and mitigates the risk of complications such as edema and ascites. For example, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, in April 2025, 17,650 new chronic hepatitis B cases were reported across 44 states and the District of Columbia in 2023, reflecting a prevalence rate of 6.1 cases per 100,000 people. Consequently, the increasing prevalence of liver diseases is a key driver for the Buminate market’s expansion. Future expansion of the Buminate market is expected to be propelled by the increase in healthcare expenditure. Healthcare expenditure signifies the total financial outlay on health services and associated activities over a defined period, typically measured annually. This rise is attributed to factors such as an aging population, the prevalence of chronic diseases, higher service costs, increased demand, technological advancements, escalating drug prices, the impact of COVID-19, medical inflation, and income disparity. Buminate benefits from higher healthcare spending, as greater investment in healthcare infrastructure and services boosts the demand for effective treatments like Buminate, especially for managing conditions such as hypoalbuminemia and trauma. This surge leads to wider market adoption, improved accessibility, and a consistent revenue stream for both manufacturers and healthcare providers. For instance, a report published by the Office for National Statistics, a UK-based government department, indicated in May 2024 that healthcare spending in the UK grew by 5.6% between 2022 and 2023, in contrast to a 0.9% increase in 2022. The total UK healthcare expenditure was approximately $317.63 billion (£292 billion) in 2023. Thus, the escalating healthcare expenditure is a significant factor driving the growth of the Buminate market.
How Is The Buminate Market Distributed Across Key Segments?
The buminate market covered in this report is segmented –
1) By Indication: Hypoproteinemia, Burn Treatment, Cardiopulmonary Bypass Surgery
2) By Distribution Channel: Hospital Pharmacies, Outpatient Clinics, Specialty Pharmacies
3) By End-Use: Hospitals, Clinics, Ambulatory Care, Home Care
Who Are The Key Market Participants In The Buminate Market?
Major companies operating in the buminate market are Grifols S.A.
Access The Complete Buminate Market Report:
https://www.thebusinessresearchcompany.com/report/buminate-global-market-report
Which Region Holds The Largest Share In The Buminate Market?
North America was the largest region in the buminate market in 2025. The regions covered in the buminate market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model